The Association of MiRNA10a and Glucose Transporters in Oral Squamous Cell Carcinoma With Diabetes: A Pilot Study

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2024 Feb 6

PMID 38318595

Authors

Sukanth R

Priyadharshini R Jr

Selvaraj Jayaraman

Sinduja Palati

Affiliations

Soon will be listed here.

Abstract

Introduction: MicroRNAs (miRNAs) are well-established post-translational non-coding RNAs that play crucial roles in mRNA degradation and repression. Glucose transporter 1 (GLUT1) showed correlation along with various miRNA, specifically miRNA10a expression in lung cancers. The role of miRNA10a along with glucose upregulation leading to cancer proliferation in oral squamous cell carcinoma (OSCC) is unknown. This study aimed to investigate the expression levels of miRNA10a and GLUT1 in OSCC patients with diabetes.

Materials And Methods: miRNA10a and GLUT1 expression were estimated in OSCC, precancerous, and healthy tissues using quantitative reverse transcriptase polymerase chain reaction (RT-PCR). miRNA10a and GLUT1 expression levels were recorded as fold change. Further, a one-way analysis of variance (ANOVA) test was performed to find whether there is any difference in miRNA10a and GLUT1 expression between OSCC, precancerous, and healthy tissues.

Results: The RT-PCR findings revealed an increased expression of miRNA10a and GLUT1 in OSCC compared to precancerous and healthy tissue. There is a positive correlation between miRNA10a and GLUT1 expression levels in both potentially malignant and control tissues, with a marked increase in cancerous tissue. This study demonstrated the significance of upregulated miRNA10a expression, indicating a direct correlation with OSCC proliferation via GLUT1 overexpression. Specifically, miRNA10a exhibited a fold change of 1.2±0.072 in potentially malignant tissue and 1.4±0.05 in cancer tissue, while GLUT1 exhibited a fold change of 1.25±0.092 in potentially malignant tissue and 0.092±0.08 in cancer tissue, respectively.

Conclusion: This research highlights the role of miRNA10a in cancer progression by facilitating proliferation through the regulation of GLUT1 in cancerous tissues, particularly in hyperglycemic conditions. This mechanism further contributes to increased glucose transport in cancer patients, which may potentially impede tumor prognosis. These findings underscore the potential significance of targeting miRNA10a and GLUT1 as therapeutic interventions in cancer management.

References

Kumari A, Jha A, Tiwari A, Nath N, Kumar A, Nagini S . Role and regulation of GLUT1/3 during oral cancer progression and therapy resistance. Arch Oral Biol. 2023; 150:105688. DOI: 10.1016/j.archoralbio.2023.105688. View

Schiliro C, Firestein B . Mechanisms of Metabolic Reprogramming in Cancer Cells Supporting Enhanced Growth and Proliferation. Cells. 2021; 10(5). PMC: 8146072. DOI: 10.3390/cells10051056. View

Quirico L, Orso F, Cucinelli S, Paradzik M, Natalini D, Centonze G . miRNA-guided reprogramming of glucose and glutamine metabolism and its impact on cell adhesion/migration during solid tumor progression. Cell Mol Life Sci. 2022; 79(4):216. PMC: 8964646. DOI: 10.1007/s00018-022-04228-y. View

Condrat C, Thompson D, Barbu M, Bugnar O, Boboc A, Cretoiu D . miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis. Cells. 2020; 9(2). PMC: 7072450. DOI: 10.3390/cells9020276. View

Chen Y, Song Y, Yu Y, Cheng W, Tong X . miRNA-10a promotes cancer cell proliferation in oral squamous cell carcinoma by upregulating GLUT1 and promoting glucose metabolism. Oncol Lett. 2019; 17(6):5441-5446. PMC: 6507447. DOI: 10.3892/ol.2019.10257. View

Ancey P, Contat C, Meylan E . Glucose transporters in cancer - from tumor cells to the tumor microenvironment. FEBS J. 2018; 285(16):2926-2943. DOI: 10.1111/febs.14577. View

Botha H, Farah C, Koo K, Cirillo N, McCullough M, Paolini R . The Role of Glucose Transporters in Oral Squamous Cell Carcinoma. Biomolecules. 2021; 11(8). PMC: 8392467. DOI: 10.3390/biom11081070. View

Li X, Ren H . Long noncoding RNA PVT1 promotes tumor cell proliferation, invasion, migration and inhibits apoptosis in oral squamous cell carcinoma by regulating miR‑150‑5p/GLUT‑1. Oncol Rep. 2020; 44(4):1524-1538. PMC: 7448409. DOI: 10.3892/or.2020.7706. View

Chauhan R, Trivedi V, Rani R, Singh U . A Study of Head and Neck Cancer Patients with Reference to Tobacco Use, Gender, and Subsite Distribution. South Asian J Cancer. 2022; 11(1):46-51. PMC: 9273320. DOI: 10.1055/s-0041-1740601. View

10.

Wang J, Lv N, Lu X, Yuan R, Chen Z, Yu J . Diagnostic and therapeutic role of microRNAs in oral cancer (Review). Oncol Rep. 2020; 45(1):58-64. PMC: 7709826. DOI: 10.3892/or.2020.7854. View

11.

Chen X, Yu J, Tian H, Shan Z, Liu W, Pan Z . Circle RNA hsa_circRNA_100290 serves as a ceRNA for miR-378a to regulate oral squamous cell carcinoma cells growth via Glucose transporter-1 (GLUT1) and glycolysis. J Cell Physiol. 2019; 234(11):19130-19140. DOI: 10.1002/jcp.28692. View

12.

Azad N, Maurya M, Kar M, Goel M, Singh A, Sagar M . Expression of GLUT-1 in oral squamous cell carcinoma in tobacco and non-tobacco users. J Oral Biol Craniofac Res. 2016; 6(1):24-30. PMC: 4756077. DOI: 10.1016/j.jobcr.2015.12.006. View

13.

Yu T, Liu L, Li J, Yan M, Lin H, Liu Y . MiRNA-10a is upregulated in NSCLC and may promote cancer by targeting PTEN. Oncotarget. 2015; 6(30):30239-50. PMC: 4745794. DOI: 10.18632/oncotarget.4972. View

14.

Solomon M, Radhakrishnan R . MicroRNA's - The vibrant performers in the oral cancer scenario. Jpn Dent Sci Rev. 2020; 56(1):85-89. PMC: 7310692. DOI: 10.1016/j.jdsr.2020.04.001. View

15.

Adekola K, Rosen S, Shanmugam M . Glucose transporters in cancer metabolism. Curr Opin Oncol. 2012; 24(6):650-4. PMC: 6392426. DOI: 10.1097/CCO.0b013e328356da72. View

16.

R Jr P, Yuwanati M, Sekaran S, M S . miRNA Associated With Glucose Transporters in Oral Squamous Cell Carcinoma: A Systematic Review. Cureus. 2023; 15(9):e46057. PMC: 10605560. DOI: 10.7759/cureus.46057. View

17.

Zambrano A, Molt M, Uribe E, Salas M . Glut 1 in Cancer Cells and the Inhibitory Action of Resveratrol as A Potential Therapeutic Strategy. Int J Mol Sci. 2019; 20(13). PMC: 6651361. DOI: 10.3390/ijms20133374. View